Pavlos Msaouel

List of Publications by Year
in descending order

113 papers	2,635 citations	236925 25 h-index	233421 45 g-index
118 all docs	118 docs citations	118 times ranked	3967 citing authors

#	Article	IF	Citations
1	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. European Urology Oncology, 2023, 6, 228-232.	5.4	11
2	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International, 2022, 129, 610-620.	2.5	22
3	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clinical Genitourinary Cancer, 2022, 20, e16-e24.	1.9	1
4	Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. European Urology Oncology, 2022, 5, 265-267.	5.4	6
5	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit. Cancer Investigation, 2022, 40, 184-188.	1.3	4
6	Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience.. Journal of Clinical Oncology, 2022, 40, 351-351.	1.6	1
7	Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC).. Journal of Clinical Oncology, 2022, 40, 356-356.	1.6	3
8	Medicine before and after David Cox. European Journal of Internal Medicine, 2022, 98, 1-3.	2.2	4
9	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
10	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine, 2022, 14, eabm6420.	12.4	29
11	Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 311-326.	3.8	3
12	Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211031.	3.2	7
13	The Big Data Paradox in Clinical Practice. Cancer Investigation, 2022, 40, 567-576.	1.3	16
14	Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nature Biotechnology, 2022, 40, 1624-1633.	17.5	31
15	Causal Diagram Techniques for Urologic Oncology Research. Clinical Genitourinary Cancer, 2021, 19, 271.e1-271.e7.	1.9	25
16	Loss of ARID1A Promotes Epithelialâ€“Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Cancer Research, 2021, 81, 332-343.	0.9	22
17	Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 134.e9-134.e16.	1.6	9
18	Systemic Therapies for the Management of Nonâ€“Clear Cell Renal Cell Carcinoma: What Works, What Doesnâ€™t, and What the Future Holds. Clinical Genitourinary Cancer, 2021, 19, 103-116.	1.9	31

#	Article	IF	Citations
19	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402.	3.4	7
20	Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. Cancers, 2021, 13, 695.	3.7	9
21	Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: A systematic review and individual patient data meta-analysis.. Journal of Clinical Oncology, 2021, 39, 317-317.	1.6	0
22	Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes.. Journal of Clinical Oncology, 2021, 39, 406-406.	1.6	0
23	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International, 2021, 128, 196-205.	2.5	18
24	Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC).. Journal of Clinical Oncology, 2021, 39, 324-324.	1.6	2
25	Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Network Open, 2021, 4, e2036321.	5.9	39
26	A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC).. Journal of Clinical Oncology, 2021, 39, 312-312.	1.6	8
27	The evolving treatment landscape of advanced urothelial carcinoma. Current Opinion in Oncology, 2021, 33, 221-230.	2.4	6
28	Combination antiangiogenic tyrosine kinase inhibition and antiâ€PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Medicine, 2021, 10, 2341-2349.	2.8	15
29	Outcomes of patients with intermediateâ€risk or poorâ€risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. International Journal of Cancer, 2021, 149, 387-393.	5.1	6
30	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist, 2021, 26, 476-482.	3.7	19
31	A cytoskeletal function for PBRM1 reading methylated microtubules. Science Advances, 2021, 7, .	10.3	17
32	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers, 2021, 13, 2170.	3.7	15
33	Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. Cancers, 2021, 13, 2741.	3.7	23
34	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. , 2021, 9, e002850.		15
35	Precision Bayesian phase Iâ€II doseâ€finding based on utilities tailored to prognostic subgroups. Statistics in Medicine, 2021, 40, 5199-5217.	1.6	15
36	Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Network Open, 2021, 4, e2122998.	5.9	13

#	Article	IF	Citations
37	Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clinical Genitourinary Cancer, 2021, 19, e401-e408.	1.9	14
38	Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials. Cancer Investigation, 2021, 39, 1-6.	1.3	10
39	Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treatment and Research Communications, 2021, 27, 100349.	1.7	3
40	TAM kinase inhibition and immune checkpoint blockadeâ€“ a winning combination in cancer treatment?. Expert Opinion on Therapeutic Targets, 2021, 25, 141-151.	3.4	17
41	Causal considerations can inform the interpretation of surprising associations in medical registries. Cancer Investigation, 2021, , 1-27.	1.3	11
42	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncology, The, 2021, 22, 1732-1739.	10.7	84
43	Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers, 2021, 13, 6022.	3.7	14
44	Truncating mutations: an insight into the biology of urinary tract carcinomas?. American Journal of Cancer Research, 2021, 11, 6214-6217.	1.4	0
45	Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. European Urology Oncology, 2020, 3, 687-694.	5.4	14
46	Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treatment and Research Communications, 2020, 23, 100166.	1.7	23
47	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2020, 26, 1845-1851.	30.7	193
48	Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Molecular and Cellular Oncology, 2020, 7, 1777060.	0.7	10
49	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open, 2020, 5, e001073.	4.5	1
50	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers, 2020, 12, 710.	3.7	3
51	Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer. Anticancer Research, 2020, 40, 709-718.	1.1	2
52	Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist, 2020, 25, 252-258.	3.7	62
53	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell, 2020, 37, 720-734.e13.	16.8	74
54	A phase Iâ€ll design based on periodic and continuous monitoring of disease status and the times to toxicity and death. Statistics in Medicine, 2020, 39, 2035-2050.	1.6	5

#	Article	IF	Citations
55	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. International Journal of Gynecological Cancer, 2020, 30, 89-93.	2.5	30
56	A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy.. Journal of Clinical Oncology, 2020, 38, 612-612.	1.6	7
57	Patient-reported outcomes on treatment-related side effects in renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 654-654.	1.6	4
58	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncology Practice, 2020, 16, e1264-e1271.	2.9	16
59	Expression of IGF-IEc Isoform in Renal Cell Carcinoma Tissues. Anticancer Research, 2020, 40, 6213-6219.	1.1	3
60	Management of Non-Clear Cell Renal Cell Carcinoma. , 2020, , 307-323.		1
61	Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clinical Genitourinary Cancer, 2019, 17, e447-e453.	1.9	34
62	Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation. Clinical Genitourinary Cancer, 2019, 17, 315-318.	1.9	9
63	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell, 2019, 35, 204-220.e9.	16.8	62
64	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 1-6.	1.9	60
65	Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?. Oncotarget, 2019, 10, 3979-3981.	1.8	15
66	A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clinical Cancer Research, 2018, 24, 2044-2049.	7.0	56
67	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e47-e57.	1.9	12
68	Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. European Journal of Cancer, 2018, 104, 188-194.	2.8	58
69	Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Current Cancer Drug Targets, 2018, 18, 177-187.	1.6	107
70	Key issues affecting quality of life and patient-reported outcomes in prostate cancer: an analysis conducted in 2128 patients with initial psychometric assessment of the prostate cancer symptom scale (PCSS). BMJ Supportive and Palliative Care, 2017, 7, bmjspcare-2016-001146.	1.6	4
71	Recent developments in the management of germ cell tumors. Current Opinion in Oncology, 2017, 29, 172-178.	2.4	3
72	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. Journal of Urology, 2017, 198, 530-537.	0.4	55

#	Article	IF	Citations
73	Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart and Vessels, 2017, 32, 969-976.	1.2	10
74	Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report. Clinical Genitourinary Cancer, 2017, 15, e73-e77.	1.9	2
75	Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?. European Urology, 2017, 71, 415-416.	1.9	1
76	Metabolic Derangements in Succinate Dehydrogenase Bâ€“Mutated Renal-Cell Carcinomas: More Than Meets the Eye?. JCO Precision Oncology, 2017, 1, 1-4.	3.0	2
77	Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice, 2017, 13, 414-421.	2.5	52
78	Primary Urinary Tract Lymphoma: Rare but Aggressive. Anticancer Research, 2017, 37, 6989-6995.	1.1	13
79	Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget, 2017, 8, 42149-42158.	1.8	6
80	Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer. Current Drug Targets, 2016, 17, 276-289.	2.1	6
81	Immune Checkpoint Therapy in Head and Neck Cancers. Cancer Journal (Sudbury, Mass), 2016, 22, 108-116.	2.0	12
82	Thrombocytopaenia as a Prognostic Indicator in Heart Failure with Reduced Ejection Fraction. Heart Lung and Circulation, 2016, 25, 568-575.	0.4	23
83	Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans. Oncotarget, 2016, 7, 67948-67955.	1.8	3
84	Primary Hepatic Small Cell Carcinoma: Two Case Reports, Molecular Characterization and Pooled Analysis of Known Clinical Data. Anticancer Research, 2016, 36, 271-7.	1.1	5
85	A vicious cycle of acute catecholamine cardiomyopathy and circulatory collapse secondary to pheochromocytoma. Oxford Medical Case Reports, 2015, 2015, 343-345.	0.4	9
86	The role of the insulin-like growth factor-1 system in breast cancer. Molecular Cancer, 2015, 14, 43.	19.2	287
87	Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. Breast Cancer Research and Treatment, 2015, 151, 679-686.	2.5	28
88	The role of KISS1/KISS1R system in tumor growth and invasion of differentiated thyroid cancer. Anticancer Research, 2015, 35, 819-26.	1.1	16
89	Review: The Role of Insulin-like Growth Factor-1 Signaling Pathways in Uterine Leiomyoma. In Vivo, 2015, 29, 637-49.	1.3	13
90	Assessment of cognitive biases and biostatistics knowledge of medical residents: a multicenter, cross-sectional questionnaire study. Medical Education Online, 2014, 19, 23646.	2.6	28

#	Article	IF	Citations
91	Research update for articles published in EJCI in 2012. European Journal of Clinical Investigation, 2014, 44, 1010-1023.	3.4	1
92	Continuing Medical Education Activity in Echocardiography. Echocardiography, 2014, 31, 751-751.	0.9	0
93	An Evidence-Based Determination of Issues Affecting Quality of Life and Patient-Reported Outcomes in Lung Cancer: Results of a Survey of 660 Patients. Journal of Thoracic Oncology, 2014, 9, 1243-1248.	1.1	52
94	Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. Heart and Lung: Journal of Acute and Critical Care, 2014, 43, 569-573.	1.6	16
95	Outcomes in World Health Organization Group II Pulmonary Hypertension: Mortality and Readmission Trends With Systolic and Preserved Ejection Fractionâ€“Induced Pulmonary Hypertension. Journal of Cardiac Failure, 2014, 20, 467-475.	1.7	32
96	Improving clinical prognostic categories beyond performance status: Enhancing accuracy in survival prediction with a three-item patient-reported outcome (PRO) index from the LCSS in lung cancer and mesothelioma.. Journal of Clinical Oncology, 2014, 32, 8065-8065.	1.6	2
97	Abstract W MP65: Accuracy of Two-Dimensional Echocardiography using Second Harmonic Imaging for the Diagnosis of Intracardiac Right-to-Left Shunt: A Meta-Analysis of Prospective Studies. Stroke, 2014, 45, .	2.0	0
98	Medical and socioeconomic factors associated with triple-negative breast cancer (TNBC) in women with health care disparities.. Journal of Clinical Oncology, 2014, 32, e17512-e17512.	1.6	0
99	Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples. Anticancer Research, 2014, 34, 2937-42.	1.1	3
100	Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. Anticancer Research, 2014, 34, 7415-24.	1.1	12
101	Oncolytic measles virus strains as novel anticancer agents. Expert Opinion on Biological Therapy, 2013, 13, 483-502.	3.1	60
102	Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opinion on Investigational Drugs, 2013, 22, 1385-1400.	4.1	12
103	The Effortâ€reward Imbalance Questionnaire in Greek: Translation, Validation and Psychometric Properties in Health Professionals. Journal of Occupational Health, 2012, 54, 119-130.	2.1	26
104	The Independent Effect of Platelet Count On Mortality in a Large Inner City Elderly Outpatient Population. Blood, 2012, 120, 4645-4645.	1.4	3
105	Multiplicative Interaction Between Mean Corpuscular Volume and Red Cell Distribution Width in Predicting Mortality of Elderly Patients with and without Anemia. Blood, 2012, 120, 5150-5150.	1.4	1
106	Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer, 2011, 11, 336.	2.6	69
107	Methods of detection of circulating melanoma cells: A comparative overview. Cancer Treatment Reviews, 2011, 37, 284-290.	7.7	22
108	Burnout and training satisfaction of medical residents in Greece: will the European Work Time Directive make a difference?. Human Resources for Health, 2010, 8, 16.	3.1	45

#	Article	IF	Citations
109	Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opinion on Investigational Drugs, 2009, 18, 1297-1316.	4.1	29
110	Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 341-355.	4.7	93
111	Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opinion on Emerging Drugs, 2007, 12, 285-299.	2.4	19
112	Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1488-94.	2.3	21
113	Greek medical studentsâ€™ career choices indicate strong tendency towards specialization and training abroad. Health Policy, 2006, 79, 101-106.	3.0	43